AITRICS (CEO Gwangjun Kim), a medical artificial intelligence (AI) specialized company, announced on the 30th that it has signed a cooperation agreement with Mayo Clinic Platform, a leading medical institution in the United States, for the joint development and verification of next-generation medical AI models.
Through this agreement, AITRIX has gained access to the massive clinical data held by the Mayo Clinic platform. This data will enable the development of general-purpose AI models applicable to real-world medical settings, laying the foundation for international validation of their performance and safety.
The Mayo Clinic Platform, a digital health organization within the Mayo Clinic in the United States, supports the development and evaluation of medical AI through world-class clinical data and research infrastructure. Through this collaboration, AITRIX plans to develop AI technology optimized for the US healthcare environment and lay the foundation for global market expansion.
In addition to jointly developing AI models, the two companies have established a strategic partnership that includes licensing and distribution collaboration. This has established a long-term collaborative system spanning from development through commercialization.
With this collaboration, AITRICS plans to launch a full-scale US clinical trial for its AI solution, "AITRICS-VC (Vital Care)," which predicts the deterioration of patient conditions within its hospitals. This solution uses patient vital data to predict the likelihood of severe deterioration and support hospital response efforts.
“This contract is an important milestone for AITRIX in its full-scale entry into the global medical market,” said Park Si-ah, AITRIX’s overseas business development manager. “Through collaboration with Mayo Clinic, a world-class medical institution, we will enhance the reliability of our technology and implement a business strategy suitable for the U.S. market.”
- See more related articles
You must be logged in to post a comment.